Cited by 152Multiple Myeloma Research and TreatmentsBone health and treatmentsLymphoma Diagnosis and Treatment

The DOI matches its Crossref record; 122 of the 123 references it cites were found in a registry or an index.

Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management

Open access

Rajkumar, S. Vincent·2011·American Journal of Hematology

DOI 10.1002/ajh.21913

Open this paper in CoChat — free account Open PDF

Abstract

Disease overview: Multiple myeloma is malignant plasma‐cell disorder that accounts for ∼∼10% of all hematologic malignancies. Diagnosis: The diagnosis requires (1) 10% or more clonal plasma cells on bone marrow examination or a biopsy‐proven plasmacytoma plus (2) evidence of end‐organ damage felt to be related to the underlying plasma cell disorder. Risk stratification: Patients with 17p deletion, t(4;14), t(14;16), t(14;20), and karyotypic deletion 13 or hypodiploidy are considered to have high‐risk myeloma. All others are considered to have standard‐risk disease. Risk‐adapted therapy: Standard‐risk patients are treated with nonalkylator‐based therapy such as lenalidomide plus low‐dose dexamethasone (Rd) followed by autologous stem‐cell transplantation (ASCT). If patients are tolerating the induction regimen treatment well, an alternative strategy is to continue initial therapy after stem‐cell collection, reserving ASCT for first relapse. High‐risk patients are treated with a bortezomib‐based induction followed by ASCT and then bortezomib‐based maintenance. Patients not eligible for ASCT can be treated with Rd for standard risk disease or a bortezomib‐based regimen if high‐risk features are present. To reduce toxicity, when using bortezomib, the once‐weekly dose is preferred; similarly, when using dexamethasone, the low‐dose approach (40 mg once a week) is preferred, unless there is a need for rapid disease control. Management of refractory disease: Patients with indolent relapse can be treated first with lenalidomide, bortezomib, or alkylators plus low‐dose corticosteroids. Patients with more aggressive relapse often require therapy with a combination of multiple active agents. The most promising new agents in development are pomalidomide and carfilizomib. Am. J. Hematol. 86:57–65, 2011. © 2010 Wiley‐Liss, Inc.

Integrity signals

Registry

Crossref · 10.1002/ajh.21913

Cites

122 of 122 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 retracted

Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial
Abdelkefi, A., Ladeb, S., Torjman, L., Othman, T. B., Lakhal, A., Romdhane, N. B., Omri, H. E., Elloumi, M., Bellâaj, H., Jeddi, R., et al. (2007) · Blood · doi:10.1182/blood-2007-07-101212 · Cited by 125
Retracted
Cancer Statistics, 2010
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
International Staging System for Multiple Myeloma
Greipp, P. R., Miguel, J. S., Durie, B. G. M., Crowley, J. J., Barlogie, B., Bladé, J., Boccadoro, M., Child, J. A., Avet-Loiseau, H., Kyle, R. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.242 · Cited by 2,974
International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Self-citation
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Self-citation
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
Richardson, P. G. G., Sonneveld, P., Schuster, M. W., Irwin, D. H., Stadtmauer, E. A., Facon, T. T. F., Harousseau, J., Ben‐Yehuda, D., Lonial, S., Goldschmidt, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043445 · Cited by 2,512
Review of 1027 Patients With Newly Diagnosed Multiple Myeloma
Kyle, R. A., Gertz, M. A., Witzig, T. E., Lust, J. A., Lacy, M. Q., Dispenzieri, A., Fonseca, R., Rajkumar, S. V., Offord, J. R., Larson, D. R., et al. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.1.21 · Cited by 2,447
Self-citation
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group
The International Myeloma Working Group (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04355.x · Cited by 2,367

Show all 123 references

Research works printed but not linked: 10

10.4065/80.10.1371 · DOI
10.1016/S0025-6196(11)61029-X · DOI
Jacobus S, 2010, Outcome of elderly patients 70 years and older with newly diagnosed myeloma in the ECOG randomized trial of lenalidomide/high‐dose dexamethasone (RD) versus lenalidomide/low‐dose dexamethasone (Rd), Haematologica, 95, 149
Barlogie B, 2003, Comparable survival in multiple myeloma (MM) with high dose therapy (HDT) employing MEL 140 mg/m2 + TBI 12 Gy autotransplants versus standard dose therapy with VBMCP and no benefit from interferon (IFN) maintenance: Results of intergroup Trial S9321, Blood, 102, 42a
Blade J, 2003, High‐dose therapy autotransplantation/intensification versus continued conventional chemotherapy in multiple myeloma patients responding to initial chemotherapy. Definitive results from PETHEMA after a median follow‐up of 66 months, Blood, 102, 42a
Attal M, 2002, Double autologous transplantation improves survival of multiple myeloma patients: Final analysis of a Prospective Randomized Study of the “Intergroupe Francophone du Myelome” (IFM 94), Blood, 100, 5a
Fermand JP, 2003, Single versus tandem high dose therapy (HDT) supported with autologous blood stem cell (ABSC) transplantation using unselected or CD34‐enriched ABSC: Results of a two by two designed randomized trial in 230 young patients with multiple myeloma (MM), Hematol J, 4, S59
Goldschmidt H, 2003, Single vs. tandem autolgous transplantation in multiple myeloma: The GMMG experience, Hematol J, 4, S61
Kumar S, 2010, Outcome of patients with myeloma relapsing after IMiD and bortezomib therapy: A multicenter study from the International Myeloma Foundation Working Group, Haematologica, 95
Berenson JR, 2003, Experience with long‐term therapy using the proteasome inhibitor, bortezomib, in advanced multiple myeloma (MM), Proc Am Soc Clin Oncol, 22, 581

Sorted by citations

Multiple myeloma
Röllig, C., Knop, S. T., & Bornhäuser, M. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60493-1 · Cited by 626
Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma
Zavidij, O., Haradhvala, N. J., Mouhieddine, T. H., Sklavenitis-Pistofidis, R., Cai, S., Reidy, M., Rahmat, M., Flaifel, A., Ferland, B., Su, N. K., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0053-3 · Cited by 374
Epidemiology, Staging, and Management of Multiple Myeloma
Padala, S. A., Barsouk, A., Barsouk, A., Rawla, P., Vakiti, A., Kolhe, R., Kota, V., & Ajebo, G. H. (2021) · Medical Sciences · doi:10.3390/medsci9010003 · Cited by 332
Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology
Kumar, S. K., Callander, N. S., Adekola, K., Anderson, L. D., Baljević, M., Campagnaro, E. L., Castillo, J. J., Chandler, J. C., Costello, C. L., Efebera, Y. A., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0057 · Cited by 283
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
Mateos, M., Blacklock, H. A., Schjesvold, F. H., Oriol, A., Simpson, D., George, A., Goldschmidt, H., Larocca, A., Chanan-Khan, A. A., Sherbenou, D. W., et al. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30110-3 · Cited by 259
Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma
Zhu, Y. X., Braggio, E., Shi, C.-X., Kortuem, K. M., Bruins, L. A., Schmidt, J. E., Chang, X.-B., Langlais, P., Luo, M., Jedlowski, P., et al. (2014) · Blood · doi:10.1182/blood-2014-02-557819 · Cited by 213
The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development
Rehman, W., Arfons, L. M., & Lazarus, H. M. (2011) · Therapeutic Advances in Hematology · doi:10.1177/2040620711413165 · Cited by 207
Myeloma as a model for the process of metastasis: implications for therapy
Ghobrial, I. M. (2012) · Blood · doi:10.1182/blood-2012-01-379024 · Cited by 191
Congenital muscular torticollis: sequela of intrauterine or perinatal compartment syndrome.
Davids, J. R., Wenger, D. R., & Mubarak, S. J. (1993) · PubMed · Cited by 179
miR-30-5p Functions as a Tumor Suppressor and Novel Therapeutic Tool by Targeting the Oncogenic Wnt/β-Catenin/BCL9 Pathway
Zhao, J., Lin, J., Zhu, D., Wang, X., Brooks, D., Chen, M., Chu, Z., Takada, K., Ciccarelli, B. T., Admin, S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3311-t · Cited by 181
A Phase IB multicentre dose‐determination study of BHQ 880 in combination with anti‐myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal‐related events
Iyer, S. P., Beck, J. T., Stewart, A. K., Shah, J. J., Kelly, K. R., ISAACS, R. E., Bilic, S., Sen, S., & Munshi, N. C. (2014) · British Journal of Haematology · doi:10.1111/bjh.13056 · Cited by 157
The bone-marrow niche in MDS and MGUS: implications for AML and MM
Ghobrial, I. M., Detappe, A., Anderson, K. C., & Steensma, D. P. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.197 · Cited by 156
Eular Textbook on Rheumatic Diseases
Adwan, M. H. (2015) · Saudi Medical Journal · doi:10.15537/1658-3175.6383 · Cited by 141
Second Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma: Impact on Progression-Free and Overall Survival
Jimenez-Zepeda, V. H., Mikhael, J. R., Winter, A., Franke, N., Masih‐Khan, E., Trudel, S., Chen, C. I., Kukreti, V., & Reece, D. E. (2011) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2011.10.044 · Cited by 117
Pathogenic Long-Lived Plasma Cells and Their Survival Niches in Autoimmunity, Malignancy, and Allergy
Winter, O., Dame, C., Jundt, F., & Hiepe, F. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1202317 · Cited by 107
The effects of cannabidiol and its synergism with bortezomib in multiple myeloma cell lines. A role for transient receptor potential vanilloid type‐2
Morelli, M. B., Offidani, M., Alesiani, F., Discepoli, G., Liberati, S., Olivieri, A., Santoni, M., Santoni, G., Leoni, P., & Nabissi, M. (2013) · International Journal of Cancer · doi:10.1002/ijc.28591 · Cited by 112
Posicionamento sobre Diagnóstico e Tratamento da Amiloidose Cardíaca – 2021
Simões, M. V., Fernandes, F., Marcondes‐Braga, F. G., Scheinberg, P., Correia, E. D. B., Rohde, L. E. P., Bacal, F., Martins, S. M., Mangini, S., Biolo, A., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20210718 · Cited by 81
Antimyeloma Effects of the Heat Shock Protein 70 Molecular Chaperone Inhibitor MAL3-101
Braunstein, M. J., Scott, S. S., Scott, C. M., Behrman, S. L., Walter, P., Wipf, P., Coplan, J. D., Chrico, W., Joseph, D. F., Brodsky, J. L., et al. (2011) · Journal of Oncology · doi:10.1155/2011/232037 · Cited by 85
Onconephrology
Salahudeen, A. K., & Bonventre, J. V. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012070690 · Cited by 76
Single cell characterization of myeloma and its precursor conditions reveals transcriptional signatures of early tumorigenesis
Boiarsky, R. P., Haradhvala, N. J., Alberge, J.-B., Sklavenitis‐Pistofidis, R., Mouhieddine, T. H., Zavidij, O., Shih, M., Firer, D. T., Miller, M. L., El‐Khoury, H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33944-z · Cited by 80
Multiple Myeloma, Version 2.2016
Anderson, K. C., Alsina, M., Atanackovic, D., Biermann, J. S., Chandler, J. C., Costello, C. L., Djulbegović, B., Fung, H. C. H., Gasparetto, C., Godby, K. N., et al. (2015) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2015.0167 · Cited by 75
The Value of 18F-FDG PET/CT after Autologous Stem Cell Transplantation (ASCT) in Patients Affected by Multiple Myeloma (MM)
Nanni, C., Zamagni, E., Celli, M., Caroli, P., Ambrosini, V., Tacchetti, P., Brioli, A., Zannetti, B. A., Pezzi, A., Pantani, L., et al. (2012) · Clinical Nuclear Medicine · doi:10.1097/rlu.0b013e318266cee2 · Cited by 69
Is Early Palliative Care Feasible in Patients With Multiple Myeloma?
Porta-Sales, J., Guerrero-Torrelles, M., Moreno‐Alonso, D., Escarre, J. S., Clapés, V., Trelis-Navarro, J., Sureda, A. M., & Sevilla-Ribosa, A. F. D. (2017) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2017.04.012 · Cited by 68
Targeting PYK2 mediates microenvironment-specific cell death in multiple myeloma
Meads, M. B., Fang, B., Mathews, L., Gemmer, J. Y., Nong, L., Rosado-Lopez, I., Nguyen, T., Ring, J., Matsui, W. H., MacLeod, A. R., et al. (2015) · Oncogene · doi:10.1038/onc.2015.334 · Cited by 60
First experience of autologous peripheral blood stem cell mobilization with biosimilar granulocyte colony- stimulating factor
Lefrère, F., Brignier, A. C., Elie, C., Ribeil, J., Bernimoulin, M. P., Aoun, C., Cortivo, L. D., Delarue, R., Hermine, O., & Cavazzana, M. (2011) · Advances in Therapy · doi:10.1007/s12325-011-0009-1 · Cited by 57
Paraproteinemic neuropathies
Raheja, D., Specht, C., & Simmons, Z. (2014) · Muscle & Nerve · doi:10.1002/mus.24471 · Cited by 49
Immunomodulatory drugs in multiple myeloma
Andhavarapu, S., & Roy, V. (2013) · Expert Review of Hematology · doi:10.1586/ehm.12.62 · Cited by 47
Expression of the cereblon binding protein argonaute 2 plays an important role for multiple myeloma cell growth and survival
Xu, Q., Hou, Y.-X., Langlais, P. R., Erickson, P. W., Zhu, J. J., Shi, C.-X., Luo, M., Zhu, Y., Xu, Y., Mandarino, L. J., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2331-0 · Cited by 45
European Perspective on Multiple Myeloma Treatment Strategies: Update Following Recent Congresses
Ludwig, H., Avet‐Loiseau, H., Bladé, J., Boccadoro, M., Cavenagh, J. D., Cavo, M., Davies, F. E., de la Rubia, J., Delimpasi, S., Dimopoulos, M. A., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0391 · Cited by 46
Cell autonomous and microenvironmental regulation of tumor progression in precursor states of multiple myeloma
Manier, S., Kawano, Y., Bianchi, G., Roccaro, A. M., & Ghobrial, I. M. (2016) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000259 · Cited by 46
Second autologous transplant as salvage therapy in multiple myeloma
Atanackovic, D., & Schilling, G. (2013) · British Journal of Haematology · doi:10.1111/bjh.12579 · Cited by 42
The multiple oral presentations of multiple myeloma
Cardoso, R. C., Gerngross, P. J., Hofstede, T. M., Weber, D. M., & Chambers, M. S. (2013) · Supportive Care in Cancer · doi:10.1007/s00520-013-1960-y · Cited by 41
Treatment of Multiple Myeloma: Thalidomide-, Bortezomib-, and Lenalidomide-Induced Peripheral Neuropathy
Koeppen, S. (2014) · Oncology Research and Treatment · doi:10.1159/000365534 · Cited by 42
Light chain deposition disease: novel biological insights and treatment advances
Jimenez-Zepeda, V. H. (2012) · International Journal of Laboratory Hematology · doi:10.1111/j.1751-553x.2012.01419.x · Cited by 39
Diagnostic and Clinical Considerations in Concomitant Bone Marrow Involvement by Plasma Cell Myeloma and Chronic Lymphocytic Leukemia/Monoclonal B-Cell Lymphocytosis: A Series of 15 Cases and Review of Literature
Alley, C. L., Wang, E., Dunphy, C. H., Gong, J. Z., Lu, C. M., Boswell, E., Burchette, J. L., & Lagoo, A. S. (2013) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2011-0696-oa · Cited by 37
The work of living with a rare cancer: multiple myeloma
Stephens, M., McKenzie, H. A., & Jordens, C. F. C. (2014) · Journal of Advanced Nursing · doi:10.1111/jan.12430 · Cited by 34
Plasma Cell Enrichment Enhances Detection of High-Risk Cytogenomic Abnormalities by Fluorescence In Situ Hybridization and Improves Risk Stratification of Patients With Plasma Cell Neoplasms
Lu, G. G., Muddasani, R., Orlowski, R. Z., Abruzzo, L. V., Qazilbash, M. H., You, M. J., Wang, Y., Zhao, M., Chen, S., Glitza, I. C., et al. (2013) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2012-0209-oa · Cited by 34
Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma without Cryopreservation
Al‐Anazi, K. A. (2012) · Bone Marrow Research · doi:10.1155/2012/917361 · Cited by 33
Decoding multiple myeloma: single-cell insights into tumor heterogeneity, immune dynamics, and disease progression
Zhao, Z., Zhao, Z., Lin, Z., Fan, L., Xiahou, Z., Dong, Y., & Weiying, B. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1584350 · Cited by 34
Iron in Multiple Myeloma
VanderWall, K., Daniels‐Wells, T. R., Penichet, M. L., & Lichtenstein, A. K. (2013) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2013007934 · Cited by 27
Combination of intravenous immunoglobulins and lenalidomide in the treatment of scleromyxedema
Brunet‐Possenti, F., Hermine, O., Marinho, E., Crickx, B., & Descamps, V. (2013) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.01.028 · Cited by 27
Total cost comparison in relapsed/refractory multiple myeloma
Durie, B. G. M., Binder, G., Pashos, C. L., Khan, Z. M., Hussein, M. A., & Borrello, I. (2013) · Journal of Medical Economics · doi:10.3111/13696998.2012.760159 · Cited by 26
Proteasome Inhibition Is Partially Effective in Attenuating Pre-Existing Immunity against Recombinant Adeno-Associated Viral Vectors
Kármán, J., Gumlaw, N., Zhang, J., Jiang, J.-L., Cheng, S. H., & Zhu, Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034684 · Cited by 26
Icing oral mucositis: Oral cryotherapy in multiple myeloma patients undergoing autologous hematopoietic stem cell transplant
Chen, J., Seabrook, J. A., Fulford, A., & Rajakumar, I. (2015) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155215620920 · Cited by 25
Bone Health, Pain, and Mobility: Evidence-Based Recommendations for Patients With Multiple Myeloma
Rome, S., Noonan, K., Bertolotti, P., Tariman, J. D., Miceli, T. S., & and Board (2017) · Clinical journal of oncology nursing · doi:10.1188/17.cjon.s5.47-59 · Cited by 26
Abdominal subcutaneous fat pad aspiration and bone marrow examination for the diagnosis of AL amyloidosis: the reliability of immunohistochemistry
Miyazaki, K., Kawai, S., & Suzuki, K. (2015) · International Journal of Hematology · doi:10.1007/s12185-015-1827-8 · Cited by 25
Impact of Genetic Abnormalities on the Prognoses and Clinical Parameters of Patients with Multiple Myeloma
Jekarl, D., Min, C., Kwon, A., Kim, H., Chae, H., Kim, M., Lim, J.-Y., Kim, Y., & Han, K. (2013) · Annals of Laboratory Medicine · doi:10.3343/alm.2013.33.4.248 · Cited by 24
HO-1 promotes resistance to an EZH2 inhibitor through the pRB-E2F pathway: correlation with the progression of myelodysplastic syndrome into acute myeloid leukemia
He, Z., Zhang, S., Ma, D., Fang, Q., Yang, L., Shen, S., Chen, Y., Ren, L., & Wang, J. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-2115-9 · Cited by 21
Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib
Chen, M.-H., Qi, C. X. Y., Reece, D. E., & Chang, H. (2011) · Human Pathology · doi:10.1016/j.humpath.2011.07.013 · Cited by 20
Auto-SCT improves survival in systemic light chain amyloidosis: a retrospective analysis with 14-year follow-up
Parmar, S., Kongtim, P., Champlin, R. E., Dinh, Y., Elgharably, Y., Wang, M., Bashir, Q., Shah, J. J., Shah, N. D., Popat, U., et al. (2014) · Bone Marrow Transplantation · doi:10.1038/bmt.2014.115 · Cited by 20
High levels of circulating CD34+ cells at autologous stem cell collection are associated with favourable prognosis in multiple myeloma
Raschle, J., Ratschiller, D., Mans, S., Mueller, B. U., & Pabst, T. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.329 · Cited by 18
Preventive strategies in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma
Rajkumar, S. V. (2012) · American Journal of Hematology · doi:10.1002/ajh.23204 · Cited by 19
Self-citation
Phase I / II study of bortezomib‐melphalan‐prednisolone for previously untreated Japanese patients with multiple myeloma
Ogawa, Y., Suzuki, K., Sakai, A., Iida, S., Ogura, M., Tobinai, K., Matsumoto, M., Matsue, K., Terui, Y., Ohashi, K., et al. (2013) · Cancer Science · doi:10.1111/cas.12172 · Cited by 18
Melphalan 100 mg/m2 with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation
Blimark, C. H., Veskovski, L., Westin, J., Rödjer, S., Brune, M. L., Hjorth, M., Holmberg, E. C., Andersson, P., & Mellqvist, U. (2011) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2011.01634.x · Cited by 18
Portal hypertension and acute liver failure as uncommon manifestations of primary amyloidosis
Norero, B., Pérez‐Ayuso, R. M., Duarte, I., Ramirez, P. A., Soza, A., Arrese, M. A., & Benítez, C. (2014) · Annals of Hepatology · doi:10.1016/s1665-2681(19)30916-0 · Cited by 18
Synthetic miR-145 mimic inhibits multiple myeloma cell growth in vitro and in vivo
Zhang, Q., Yan, W., Bai, Y., Xu, H., Fu, C., Zheng, W., Zhu, Y., & Ma, J. (2014) · Oncology Reports · doi:10.3892/or.2014.3591 · Cited by 18
Retracted
European Medicines Agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy
Tzogani, K., Florez, B., Markey, G., Caleno, M., Olimpieri, O. M., Melchiorri, D., Hovgaard, D., Sarac, S. B., Penttilä, K., Lapveteläinen, T., et al. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000570 · Cited by 17
2,4-Dihydroxy-3′-methoxy-4′-ethoxychalcone suppresses cell proliferation and induces apoptosis of multiple myeloma via the PI3K/akt/mTOR signaling pathway
Zhu, F.-C., Jiang, D., Zhang, M.-H., & Zhao, B. (2019) · Pharmaceutical Biology · doi:10.1080/13880209.2019.1662814 · Cited by 15
Genomic profiling of plasma cell disorders in a clinical setting: integration of microarray and FISH, after CD138 selection of bone marrow
Berry, N., Bain, N. L., Enjeti, A. K., & Rowlings, P. (2013) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2013-201691 · Cited by 16
The pharmacological basis for application of cannabidiol in cancer chemotherapy
Zhelyazkova, M., Kirilov, B., & Momekov, G. (2020) · Pharmacia · doi:10.3897/pharmacia.67.e51304 · Cited by 16
Discovery of potential novel CRBN modulators by virtual screening and bioassay
Xiong, F., Kong, L., Chen, L., Xue, M., Cao, F., Zhang, S., Li, H., Yan, H., Li, Y., & Zuo, Z. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114355 · Cited by 16
Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma
Kiyota, M., Kobayashi, T., Fuchida, S., Yamamoto‐Sugitani, M., Ohshiro, M., Shimura, Y., Mizutani, S., Nagoshi, H., Sasaki, N., Nakayama, R., et al. (2012) · International Journal of Hematology · doi:10.1007/s12185-012-1035-8 · Cited by 15
Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma
Doo, N. W., Thompson, P. A., Prince, H. M., Seymour, J. F., Ritchie, D., Stokes, K. H., Burbury, K., Wolf, M. M., Joyce, T., & Harrison, S. J. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.746682 · Cited by 14
Subcutaneous bortezomib for multiple myeloma treatment: patients’ benefits
Petrucci, M. T., Finsinger, P., Gentilini, F., & Chisini, M. (2014) · Patient Preference and Adherence · doi:10.2147/ppa.s38142 · Cited by 15
Adverse Prognostic Factors for Morbidity and Mortality During Peripheral Blood Stem Cell Mobilization in Patients with Light Chain Amyloidosis
Yeh, J. C., Shank, B. R., Milton, D. R., & Qazilbash, M. H. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.11.040 · Cited by 15
Second- and third-line treatment strategies in multiple myeloma: a referral-center experience
Goldman‐Mazur, S., Visram, A., Rajkumar, S. V., Kapoor, P., Dispenzieri, A. A., Lacy, M. Q., Gertz, M. A., Buadi, F. K., Hayman, S. R., Dingli, D., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00757-8 · Cited by 14
Self-citation
Effectiveness of targeted therapy as monotherapy or combined therapy in patients with relapsed or refractory multiple myeloma: A systematic review and meta-analysis
Łopuch, S., Kawalec, P., & Wiśniewska, N. (2014) · Hematology · doi:10.1179/1607845414y.0000000159 · Cited by 14
Synchronous Occurrence of Prostate Carcinoma and Multiple Myeloma: A Case Report
Sehgal, T., Sharma, S., Naseem, S., Varma, N., Das, A., & Sharma, S. (2014) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-014-0410-4 · Cited by 14
Multiple Myeloma with Biclonal Gammopathy Accompanied by Prostate Cancer
Kim, N. Y., Gong, S. J., Kim, J., Youn, S. M., & Lee, J.-A. (2011) · Annals of Laboratory Medicine · doi:10.3343/kjlm.2011.31.4.285 · Cited by 14
Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma
Jimenez-Zepeda, V. H., Reece, D. E., Trudel, S., Chen, C. I., Tiedemann, R. E., & Kukreti, V. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.719614 · Cited by 13
Interactions between SNPs affecting inflammatory response genes are associated with multiple myeloma disease risk and survival
Nielsen, K. R., Rodrigo-Domingo, M., Steffensen, R., Bæch, J., Bergkvist, K. S., Oosterhof, L., Schmitz, A., Bødker, J. S., Johansen, P., Vogel, U. B., et al. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1306643 · Cited by 15
A Case of Localized Amyloid Light-Chain Amyloidosis in the Small Intestine
Choi, J. H., Ko, B. M., Kim, C., Kim, H. K., Han, J. P., Hong, S. J., Moon, J. H., & Lee, M. S. (2014) · Intestinal Research · doi:10.5217/ir.2014.12.3.245 · Cited by 13
Heavy/light chain assay in the monitoring of multiple myeloma
Ting, H. Y., Sthaneshwar, P., Bee, P. C., Shanmugam, H., & Lim, M. (2019) · Pathology · doi:10.1016/j.pathol.2019.04.002 · Cited by 13
New Rising Infection: Human Herpesvirus 6 Is Frequent in Myeloma Patients Undergoing Autologous Stem Cell Transplantation after Induction Therapy with Bortezomib
Horowitz, N., Oren, I., Lavi, N., Zuckerman, T., Benyamini, N., Kra-oz, Z., Held, V., & Avivi, I. (2012) · Bone Marrow Research · doi:10.1155/2012/409765 · Cited by 12
Quantitative analysis of CKS1B mRNA expression and copy number gain in patients with plasma cell disorders
Stella, F., Pedrazzini, E., Baialardo, E. M., Fantl, D. B. E., Schutz, N. P., & Slavutsky, I. R. (2014) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2014.05.006 · Cited by 12
Myeloma cell morphology and morphometry in correlation with clinical stages and survival
Seili‐Bekafigo, I., Valković, T., Babarović, E., Duletić‐Načinović, A., & Jonjić, N. (2013) · Diagnostic Cytopathology · doi:10.1002/dc.22986 · Cited by 11
Retrospective analysis of 264 multiple myeloma patients
Geng, C., Liu, N., Yang, G., Liu, A., Leng, Y., Wang, H., Li, L., Wu, Y., Li, Y., & Chen, W.-M. (2012) · Oncology Letters · doi:10.3892/ol.2012.1018 · Cited by 11
Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement
Badar, T., Cornelison, A. M., Shah, N. D., Bashir, Q., Parmar, S., Patel, K. K., Hosing, C. M., Popat, U., Weber, D. M., Thomas, S. K., et al. (2016) · European Journal Of Haematology · doi:10.1111/ejh.12736 · Cited by 11
Utilizing BMP-2 muteins for treatment of multiple myeloma
Seher, A., Lagler, C., Stühmer, T., Müller-Richter, U. D. A., Kübler, A. C., Sebald, W., Müller, T. D., & Nickel, J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0174884 · Cited by 10
Incidental Discovery of a Testicular Plasmacytoma at Initial Presentation of Multiple Myeloma
Hathaway, A. R. (2013) · Case Reports in Hematology · doi:10.1155/2013/752921 · Cited by 10
Imaging Features of Extramedullary, Relapsed, and Refractory Multiple Myeloma involving the Liver Across Treatment With Cyclophosphamide, Lenalidomide, Bortezomib, and Dexamethasone
Saboo, S. S., Fennessy, F. M., Benajiba, L., Laubach, J. P., Anderson, K. C., & Richardson, P. G. G. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.1413 · Cited by 10
Autologous stem cell transplantation in multiple myeloma is not dead but alive and well
Martino, M. V., & Morabito, F. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.988611 · Cited by 10
TSCM-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial
Tseng, H., Dholaria, B., Cranert, S. A., Richter, M., Marquez, K., Cho, B. S., Bacong, A., McArthur, K., Eskew, J. D., McCaigue, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-65267-0 · Cited by 10
Ontology driven decision support systems for medical diagnosis - an interactive form for consultation in patients with plasma cell disease.
Guefack, V. D., Bertaud, V., Régis Duvauferrier, A., Bourdé, A., Morelli, J. N., & Lasbleiz, J. (2012) · PubMed · Cited by 9
Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma
Sarasquete, M. E., Martínez‐López, J., Chillón, C., Alcoceba, M., Corchete, L. A., Paiva, B., Puig, N., Sebastián, E., Jiménez, C., Mateos, M., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12519 · Cited by 9
TRIM44, a Novel Prognostic Marker, Supports the Survival of Proteasome-Resistant Multiple Myeloma Cells
Vu, T., Wang, Y., Fowler, A., Simieou, A., & McCarty, N. (2024) · Cells · doi:10.3390/cells13171431 · Cited by 8
Therapeutic Potential of Cannabinoids on Tumor Microenvironment: A Molecular Switch in Neoplasia Transformation
Bakshi, H. A., Hakkim, F. L., Ravesh, Z., Ansari, P., Hannan, J. M. A., Hashimoto, R., Takayama, K., Farzand, R., Nasef, M. M., Mensah, A., et al. (2022) · Integrative Cancer Therapies · doi:10.1177/15347354221096766 · Cited by 8
The Changing Landscape of Multiple Myeloma
Kurtin, S. E., & Faiman, B. M. (2013) · Clinical journal of oncology nursing · doi:10.1188/13.cjon.s2.7-11 · Cited by 8
Cancer testis antigen MAGE C1 can be used to monitor levels of circulating malignant stem cells in the peripheral blood of multiple myeloma patients
Shires, K., & Wienand, K. (2016) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-016-2231-3 · Cited by 8
The anti-myeloma activity of bone morphogenetic protein 2 predominantly relies on the induction of growth arrest and is apoptosis-independent
Lagler, C., El‐Mesery, M., Kübler, A. C., Müller-Richter, U. D. A., Stühmer, T., Nickel, J., Müller, T. D., Wajant, H., & Seher, A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0185720 · Cited by 8
DNA ploidy and morphology of colon tumors in the adenoma–carcinoma sequence
Staarmann, J., Kotb, W. F. M. A., & Petersen, I. (2015) · Folia Histochemica et Cytobiologica · doi:10.5603/fhc.a2015.0001 · Cited by 9
The Importance of Alliance between Hematologists and Dentists: A Retrospective Study on the Development of Bisphosphonates Osteonecrosis of the Jaws (Bronj) in Multiple Myeloma Patients
Bacci, C., Cerrato, A., Dotto, V., Zambello, R., Barilà, G., Liço, A., Semenzato, G., Stellini, E., & Zanette, G. (2021) · Dentistry Journal · doi:10.3390/dj9020011 · Cited by 7
Repositioning the Repurposed Drug, a Structural Study of Thalidomide Analogs
Rahmat, M., Sklavenitis‐Pistofidis, R., & Ghobrial, I. M. (2019) · The Hematologist · doi:10.1182/hem.v16.3.9556 · Cited by 6
Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytowego na rok 2012
Dmoszyńska, A., Walter‐Croneck, A., Mańko, J., Usnarska‐Zubkiewicz, L., Stella-Holowiecka, B. M., Walewski, J. A., Charliński, G., Wiktor-Jędrzejczak, W., Wiater, E., Lech‐Marańda, E., et al. (2012) · Acta Haematologica Polonica · doi:10.1016/s0001-5814(12)31003-7 · Cited by 6
Phase II clinical trial of personalized VCD-VTD sequential therapy using the Vulnerable Elders Survey-13 (VES-13) for transplant-ineligible patients with newly diagnosed multiple myeloma
Nakazato, T., Hagihara, M., Sahara, N., Tamai, Y., Ishii, R., Tamaki, S., Wake, A., Tajika, K., Sakai, R., Kobayashi, T., et al. (2021) · Annals of Hematology · doi:10.1007/s00277-021-04592-y · Cited by 6
Analysis on the Alpinia katsumadai components of Zingiberaceae plants and their functions on myeloma resistance
Wang, J. (2015) · Pakistan Journal of Pharmaceutical Sciences · doi:10.36721/pjps/28/3(sup)/2015/244/1065-1068 · Cited by 6
Bilateral Pleural Effusions due to Pulmonary Amyloidosis as the Presenting Manifestation of Multiple Myeloma
Agarwal, A., Singla, S., Bansal, M., & Nair, B. P. (2012) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2012.010 · Cited by 6
Variant Burkitt-type translocation (8;22)(q24;q11) in plasma cell myeloma
Kim, H., Moon, H., Hur, M., Yun, Y., Park, C. M., & Lee, M. H. (2011) · The Korean Journal of Hematology · doi:10.5045/kjh.2011.46.2.135 · Cited by 5
Atypical Presentation of Plasma Cell Leukemia Secondary to Multiple Myeloma Detected by F-18 FDG PET/CT
Cocciolillo, F., Treglia, G., Villani, M. F., & Giordano, A. (2011) · Clinical Nuclear Medicine · doi:10.1097/rlu.0b013e3182335fb7 · Cited by 5
Risk Stratification in Multiple Myeloma in Indian Settings
Kapoor, R., Kumar, R., & Dubey, A. (2019) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-019-01240-4 · Cited by 5

Authors: Rajkumar, S. V.
Affiliations: Mayo Clinic (US)
Corresponding author: Rajkumar, S. Vincent
ORCID: Rajkumar, S. Vincent
Venue: American Journal of Hematology
Publisher: Wiley
Published: 2010-12-22
Volume: 86
Issue: 1
Pages: 57-65
ISSN: 0361-8609 (ISSN-L)
1096-8652
DOI: 10.1002/ajh.21913
OpenAlex: W2121283512
Cited by: 152
References: 123
Citations by year: 2026: 1 · 2025: 3 · 2024: 4 · 2023: 2 · 2022: 7 · 2021: 6 · 2020: 4 · 2019: 10 · 2018: 3 · 2017: 9 · 2016: 7 · 2015: 10 · 2014: 20 · 2013: 23 · 2012: 24
FWCI: 3.28
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: American Journal of Hematology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
Health Sciences › Medicine › Oncology › Bone health and treatments
Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
Keywords: multiple myeloma, diagnosis, risk stratification, high-risk myeloma, lenalidomide, bortezomib, autologous stem cell transplantation, maintenance therapy, relapsed multiple myeloma, low-dose dexamethasone, 17p deletion, plasmacytoma, pomalidomide
MeSH terms: Antineoplastic Combined Chemotherapy Protocols, Humans, Multiple Myeloma, Risk Factors, Survival Rate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks